Molecular Drivers of Prostate Cancer Metastasis: Emerging Targets for Precision Therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Prostate cancer (PCa) is a leading cause of cancer death in men, particularly when it metastasizes.
• Metastasis involves complex molecular signaling pathways enabling cancer cell detachment and secondary tumor formation.
• Current treatments like androgen deprivation therapy and chemotherapy are insufficient for metastatic and castration-resistant PCa (CRPC).

Purpose of the Study:

• To investigate the molecular mechanisms driving prostate cancer metastasis.
• To review current and emerging therapeutic strategies targeting these pathways.
• To explore the potential of combined therapies and precision medicine for improved outcomes.

Main Methods:

• Review of molecular pathways involved in PCa metastasis, including PI3K/AKT, Wnt/β-catenin, and EMT.
• Analysis of current treatment limitations for metastatic and CRPC.
• Exploration of novel therapeutic targets and combination strategies.

Main Results:

• Deregulation of PI3K/AKT, Wnt/β-catenin, and EMT pathways significantly contributes to PCa spread and treatment resistance.
• Targeting these pathways, alongside immunotherapy and personalized medicine, presents promising therapeutic avenues.
• Liquid biopsy technologies offer real-time monitoring of disease progression and treatment response.

Conclusions:

• Blocking key molecular pathways (AKT, Wnt) and reversing EMT are crucial for effective PCa metastasis treatment.
• Integrated approaches combining novel therapies, immunotherapy, and precision medicine can enhance therapeutic benefits and minimize side effects.
• Future strategies focusing on molecular targets and personalized care hold the key to improved outcomes for metastatic prostate cancer patients.